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Abstract
Background: Few reports have investigated the association between human T-lymphotropic virus type 1 (HTLV-1)
and tuberculosis (TB) in countries where both infections are endemic. This study estimates the incidence of TB in a
cohort infected with HTLV-1, compared with non-infected individuals, over a ten-year period.
Methods: Retrospective cohort study involving the cross-matching of records of individuals for whom a HTLV
serology was performed at a referral center for HTLV (CHTLV) with a database of TB cases from Sinan—the
Information System on Diseases of Compulsory Declaration between 2002 and 2012.
Results: From a cohort of 6,495 individuals, 1,711 were infected with HTLV-1. A total of 73 TB cases occurred during
the study period: 33 HTLV-1-infected patients and 40 uninfected individuals. The incidence density for TB in the
HTLV-1 infected group was 3.3 person-years per 1,000 individuals and 1.1 person-years per 1,000 individuals in the
group HTLV-1 uninfected group. The relative risk of developing TB in the group of patients infected with HTLV-1
was 2.6 (CI 95 % 1.6–4.2) in comparison with HTLV-1 uninfected group. Compared to individuals with isolated TB,
those in the HTLV-1 infected group who had TB were older (p = 0.005) and had lower education levels (p = 0.02).
No differences were observed with respect to the clinical/radiological presentation, nor in the outcome of TB and
prevalence of HIV infection, when comparing among the HTLV-1-infected and uninfected groups.
Conclusions: Patients infected with HTLV-1 are more susceptible to TB. The epidemiological characteristics of
HTLV-1/TB subjects and those infected with TB overlap.
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Background
Human T-lymphotropic virus type 1 (HTLV-1) infects
around 10 million people worldwide, most of whom are
concentrated within endemic areas in developing coun-
tries. Brazil is one of the largest endemic areas of HTLV-1
in the world [1]. This virus is also recognized as the
etiological agent of adult T-cell leukemia/lymphoma
(ATLL) [2], HTLV-1-associated myelopathy/tropical spas-
tic paraparesis (HAM/TSP) [3] and HTLV-1-associated
uveitis [4], which, together, affect between 5–10 % of all
HTLV-1 infected individuals [5]. Other clinical manifesta-
tions, such as arthritis, overactive bladder, myositis and
bronchiectasis are also frequently present in infected
individuals, attesting to the systemic nature of this viral
infection [6–8].
Several reports have indicated that HTLV-1 may promote
some degree of immunosuppression, as an association has
been observed between HTLV-1 and Norwegian scabies
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[9, 10], disseminated strongyloidiasis [11] and infective
dermatitis [12]. Moreover, healthy HTLV-1 carriers ex-
hibit a suppressed response to the tuberculin skin test
(TST) [13] and their cells fail to respond to recall anti-
gens in vitro, such as recombinant purified protein de-
rivative (PPD) [14]. Previous studies that have investigated
the association between tuberculosis (TB) and HTLV-1,
which were conducted in areas endemic for both infec-
tions, found a higher prevalence of HTLV-1 infection in
patients diagnosed with tuberculosis (TB) in comparison
to these patients’ relatives or control groups [15–19].
Conversely, other authors did not detect a significant
prevalence of HTLV-1 in TB groups compared with con-
trols [20, 21]. In addition, scattered reports have shown
contradictory results with respect to the clinical outcomes
of patients infected with both HTLV-1 and TB. While
some of these reports described higher mortality in co-
infected patients compared to those with isolated TB
[22, 23], another found no differences regarding mor-
tality or clinical characteristics [24].
Salvador, the capital of the state of Bahia, located in
Northeastern Brazil, has been described as the epicenter
of the HTLV-1 endemic in the country, with a high
prevalence of infection in blood donors (1.35 %) [25], preg-
nant women (0.88 %) [26] and in the general population
(1.74 %) [27]. The state of Bahia ranks third in terms of
number of TB cases nationwide, and the incidence in
Salvador reaches 62.3/100,000 inhabitants [28]. Taking
into account the fact that both infections typically affect
economically vulnerable populations, we hypothesized
that the incidence of TB may be higher in individuals
infected with HTLV-1 in areas in which both infections
are endemic. Accordingly, the present study aimed to
estimate the incidence of TB in a cohort infected with
HTLV-1, compared with non-infected individuals, over
a ten-year period.
Methods
Area and study population
This retrospective cohort study involved the cross-matching
of records of individuals for whom HTLV serology was
performed at a referral center for HTLV (CHTLV) of the
Bahiana School of Medicine and Public Health (EBMSP),
in Salvador – Brazil, between 2002 and 2012. CHTLV is a
free public outpatient clinic that has provided comprehen-
sive care to HTLV-infected individuals and their relatives
since 2002. Serological testing for HTLV-1/2 was con-
ducted for 6,620 individuals at CHTLV throughout the
period of study. This population consisted mainly of blood
donors, pregnant women and patients with neurological
symptoms, as well as their families, who were referred by
blood banks, prenatal physicians or clinicians from the
public health system. All individuals who underwent sero-
logic testing for HTLV during the period of the study were
included. Individuals with indeterminate serology, as well
as those who tested positive for HTLV-2 and whose date
of testing was not recorded, were excluded. To perform
HTLV-1 diagnosis, all individuals were screened using
ELISA (Cambridge Biotech Corp., Worcester, MA) and
positive tests were subsequently submitted to Western
Blot analysis (HTLV blot 2.4, MP Diagnosis, Singapore)
to confirm infection. HTLV-1/2 co-infection was deter-
mined using WB, in accordance with manufacturer’s in-
structions: i) HTLV-1: reactivity to GAG (p19 with or
without p24) and two ENV (GD21 and rgp46-I) proteins;
ii) HTLV-2: reactivity to GAG (p24 with or without p19)
and two ENV (GD21 and rgp46-II) proteins. PCR was
used only in cases in which HTLV serology was indeter-
minate; however, these patients with this serological status
were excluded. The EBMSP Institutional Review Board
approved the present study.
Study design and data collection
This retrospective cohort study was based on patient
records from CHTLV and on the TB registry from the
Information System on Diseases of Compulsory Declar-
ation (Sistema de Informação de Agravos de Notificação—
Sinan). TB notification has been mandatory in Brazil since
1998. The number of TB cases reported by the SINAN
database was 79,942 in Bahia state between January 2002
and May 2012. After the exclusion of duplicates (5,211) or
corrupted names (3), the final number of TB cases was
74,454 (93.1 %). Case of tuberculosis was defined as a pa-
tient who experienced respiratory symptoms and had a
smear-positive test for Mycobacterium tuberculosis. TB
diagnosis was also considered in presence of a positive
culture or clinical history of TB associated with com-
plementary tests, for example a suggestive chest X-ray
with heterogeneous opacity of the lung parenchyma,
cavitation, nodules or consolidations [29]. Search for TB
case notifications was done in Sinan database using SQL
(Structured Query Language for use in relational data-
bases) to identify patients with records at both CHTLV
and in the Sinan registry by employing a “linkage” strategy
(record linkage). The key variables considered were pa-
tient full name, date of birth and mother’s full name.
Following patient identification, the epidemiological and
clinical variables of interest were: age at time of TB
diagnosis, gender, education level, admission status (new
case, relapse), result of chest X-ray, TST result, clinical
form of tuberculosis (pulmonary or extrapulmonary),
HIV status and TB treatment outcome. All data analyzed
were anonymized.
Statistical analysis
For purposes of analysis, subjects were classified into two
groups according to the results of serology for HTLV-1.
The independent variable was HTLV-1 and the outcome
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was the diagnosis of TB. The data were expressed as mean
and standard deviation, proportions, measures of central
tendency and interquartile range. In order to test the
differences between means Student t was used and for
proportions, the chi-square test. As measures of fre-
quency, incidence density for both groups was calculated:
coinfected (HTLV-1/TB) and isolated TB and the relative
risk of TB in those infected with HTLV-1. The date of the
serology was considered as the moment of inclusion in
the cohort. The TB disease incidence density in both
HTLV-1-infected and uninfected groups was calculated
as the number of new-TB cases per 1000 person-years
of follow-up. The analysis was further stratified by the
age and the crude incidence density was adjusted using
Mantel-Hansel test. Then, a multivariate analysis using
the Poisson model was performed considering person-time
and age and sex as potential confounding. A P < 0.05 was
considered statistically significant. All analyzes were
performed using STATA 13 statistical software (Stata
Corp, College Station, TX, USA).
Results
From January 2002 to April 2012, 6,620 individuals were
tested for HTLV-1/2 at the CHTLV, 125 of whom were
excluded (Fig. 1). The number of individuals infected
with HTLV-1 was 1,711 (1,703 had HTLV-1 and eight
were co-infected with both HTLV-1 and HTLV-2), while
4,784 had negative HTLV serology. The mean age of in-
dividuals either infected or uninfected with HTLV-1 was
43.5 ± 16.6 years and 33.3 ± 18.0 years (p = 0.000), re-
spectively. The percentage of females was 82.9 % in the
HTLV-1 infected group and 67.5 % in the uninfected
group (p = 0.000). The final sample consisted of 6,495
individuals, with a total of 46,634 person-years of follow-
up (mean 6.4 ± 2.7 years). A total of 73 cases of TB oc-
curred in members of the cohort during the period
studied: 33 among patients infected with HTLV-1 and
40 in the uninfected group. No TB cases were found
among patients coinfected with both HTLV-1 and HTLV-2.
About half the individuals (52 %) received a positive TB
diagnosis prior to being diagnosed with HTLV-1, with a
mean time difference between TB and HTLV-1 diagno-
ses of -1 ± 4 years. The overall incidence density for the
HTLV-1/TB group was 3.3 person-years per 1,000 indi-
viduals and 1.1 person-years per 1,000 individuals in
the non-infected control group. The overall relative risk
of TB in the HTLV-1-infected group was 2.6 (CI 95 %
1.6–4.2). When the sample was stratified by age, a signifi-
cantly higher relative risk of TB (3.4, CI 95 % 1.6–7.2)
was found only in individuals aged 31 to 50. The Poisson
model returned a relative risk of TB, adjusted for age
and sex, of 2.5 (IC95% 1.6–4.1) for HTLV-1 infected
individuals, in comparison with uninfected persons
(Table 1).
Fig. 1 Flow diagram of studied patients
Grassi et al. BMC Infectious Diseases  (2016) 16:491 Page 3 of 7
The majority of individuals in the HTLV-1/TB group
(54.8 %) had not completed primary school, while this
proportion was 21.7 % in the isolated TB group (p =
0.009), (Table 2).
Table 3 delineates the clinical characteristics of all indi-
viduals with TB. The frequency of chest X-ray suggestive
of TB was similar in HTLV-1 infected individuals and
those with isolated TB. The proportion of patients that
had a recurrence of TB, and/or those who abandoned
treatment and then subsequently resumed it, was slightly
higher in individuals infected with HTLV-1 (21.2 %) com-
pared to the HTLV-uninfected group (12.5 %), yet no stat-
istical significance was detected (p = 0.09). The clinical
presentations of TB (pulmonary/extra pulmonary) were
similar in all individuals. No significant differences in TB
outcomes (cure, treatment dropout or mortality) were ob-
served when comparing the HTLV-1 infected and unin-
fected groups, although two HTLV-1-infected individuals
died due to TB. TST was performed in 21.2 % of the indi-
viduals infected with HTLV-1 and in 30 % of individuals
with TB. The proportion of reactive results ≥10 mm was
75.1 % (4 of 7) in the group infected with HTLV-1 and
83 % (10 of 12) in the TB-only group. HIV serology was
positive for 6.0 % of the individuals infected with HTLV-1,
versus 12.5 % with isolated TB (p = 0.45).
Discussion
This is the first retrospective cohort study to assess the
risk of developing TB in HTLV-1-infected individuals
residing in a high TB-burden country. The results herein
indicate that the risk of developing TB in HTLV-1-
infected individuals is almost three times greater than in
uninfected controls over a 10-year period of follow-up.
This finding is particularly relevant because all studies
addressing the association between HTLV-1 and TB to
date have been carried out in populations that were pre-
viously diagnosed with TB. Moreover, several of these
studies reported contradictory results; i.e. some found an
increased prevalence of TB in HTLV-1 infected individ-
uals [15–19], while others failed to confirm this associ-
ation [20, 21]. The present study found an overall TB
incidence density of 3.3 per 1,000 person-years in the
HTLV-1-infected group. A higher risk of TB was found
mainly in individuals aged 31 to 50 years. These findings
corroborate a case control study carried out in Salvador-
Bahia that found a three times greater risk of HTLV-1
infection in patients diagnosed with TB, compared to
those without TB [18]. In HTLV-1 uninfected group, the
incidence density reached 1.1 per 1,000 person-years,
which represents a higher incidence than that found in
the general population. The uninfected group consisted
of blood donors, which are generally healthy, but also
pregnant women, patients with neurological symptoms
and relatives of HTLV-1-infected individuals for whom a
serological HTLV-1 test had been recommended. Thus,
this group is not representative of general population.
Moreover, individuals were mostly from Salvador, which
presented an annual TB incidence of 62.3/100,000 in-
habitants in general population in 2012 [30], compared
with a national incidence of 35.4/100,000 [31]. Taken to-
gether, these data strongly suggest that an association
exists between HTLV-1 and TB in areas in which both
infections are endemic.
Differences in sociodemographic characteristics were
observed between patients with HTLV-1+/TB versus the
group with TB alone. The epidemiological profile of
patients coinfected with HTLV-1/M. tuberculosis was
consistent with the epidemiological characteristics de-
scribed by a population-based study conducted in Salvador
to determine HTLV-1 infection prevalence [27]: a mean
age of 50 years at time of TB diagnosis, lower educational
level, predominance of females. Dourado et al. reported a
Table 1 Tuberculosis incidence density and relative risk stratified by age
HTLV-1-infected group HTLV-1 uninfected controls
TB cases Person year ID/1000 TB cases Person year ID/1000 RR CI 95 %
0 to 30ys 4 2,254 1.8 19 19,845 1.1 1.9 0.6–5.5
31 to 50ys 15 4,477 3.4 12 12,058 1.0 3.4 1.6–7.2
>50ys 14 3,263 4.3 9 4,737 1.9 2.3 1.0–5.2
All 33 9,994 3.3 40 36,640 1.1 2.6 1.6–4.2
Age at the TB diagnosis. HTLV-1 = Human T-lymphotropic virus type 1; TB = tuberculosis; ID = Incidence density RR- relative risk adjusted using Mantel-Hansel test
CI: confidence interval
Table 2 Epidemiological characteristics of 73 patients with
tuberculosis diagnosis according to HTLV-1 infection
Characteristics HTLV-1-infected HTLV-1-uninfected
n = 33 % n = 40 % p value*
Age (years) Mean ± SD 49.7 ± 16.4 38.6 ± 15.9 0.005
Female 22 66.7 23 57.5 0.43
Educational level 0.009
Incomplete elementar 17 54.8 2 21.7
Completed elementar 10 32.3 7 30.4
High school graduate 4 12.9 11 47.8
Age at the TB diagnosis. HTLV-1 = Human T-lymphotropic virus type 1; TB =
tuberculosis; *Pearson Chi square, P < 0.05
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1.76 % overall prevalence of HTLV-1, with a higher preva-
lence observed in women (9.3 %) over 51 years compared
to men (6.3 %), as well as in individuals with less education
and lower income. Although lower income is also associ-
ated with increased susceptibility to TB in Brazil [32], this
disease is more frequently diagnosed in men under 50. In
addition, TB burden varies according to geographic region.
Bahia is the third state in terms of absolute number of
cases, and Salvador has the second highest incidence of
TB among the capitals in northeastern Brazil [28]. These
data indicate that HTLV-1-infected individuals who are
impoverished and possess low educational levels may
suffer from greater susceptibility to TB.
Clinical features of TB infection between the two groups
revealed that the clinical presentations (pulmonary or
extra-pulmonary) and the number of chest-X-rays suggest-
ive of TB were similar. Although a greater number of indi-
viduals in the coinfected group had higher rates of TB
recurrence or returned to treatment after abandonment,
this difference was not statistically significant. A positive
TST result was more frequently observed among individ-
uals serologically negative for HTLV-1 (25 %), compared
with 12.1 % of patients with HTLV-1/TB, which may indi-
cate some degree of immunosuppression in response to
antigens of M. tuberculosis. However, this result should be
carefully interpreted since only one-third of the subjects
in both groups had TST results registered in their medical
records.
Nonetheless, a decreased response to TST was reported
in a cohort of patients infected with HTLV-1 in Japan [16],
and a decreased proliferative response to purified protein
derivate (PPD) was also described in asymptomatic individ-
uals infected with HTLV-1 in Salvador-Brazil [17]. Con-
versely, another study did not find any differences in the
number of patients with a positive TST result when com-
paring individuals with HTLV-1/TB or isolated TB [24].
Regarding HIV-1 serological status, the percentage of indi-
viduals co-infected by this virus in the HTLV-1/TB group
was half that of the group with TB alone (12 %), and simi-
lar to the overall rate of HIV found by testing patients with
Table 3 Characteristics and outcomes of tuberculosis in patients infected with HTLV-1 compared to uninfected
Variables associated to TB HTLV-infected (n = 33) HTLV-1-uninfected (n = 40) p value*
N % n %
Admission status 0.09
New case 19 57.6 32 80
Relapse/readmission 7 21.2 5 12.5
Chest X ray 0.55
Suspecta 28 84.9 30 75
Normal 2 6.0 5 12.5
Others 3 9.1 5 12.5
Clinical form of TB 0.71
Pulmonary 28 84.8 31 77.5
Extra-pulmonary 5 15.2 7 17.5
Both - - 2 5
TB outcome 0.54
Healing/diagnosis change 22 66.7 29 72.5
Abandonment/death/transfer 2 6.1 4 10
Other 9 27.3 7 17.5
TST ND
Non reactor 2 6.1 1 2.5
>5 and <10 mm 1 3 1 2.5
>10 mm 4 12.1 10 25
Not performed 26 78.8 28 70
HIV serology 0.45
Positive 2 6.0 5 12.5
Negative 29 89 34 85
Not performed 2 6.0 1 2.5
HTLV-1 = Human T-lymphotropic virus type 1; TB = Tuberculosis; TST = tuberculin skin test; HIV = human immunodeficiency virus; aheterogeneous opacity of the
lung parenchyma, cavitation, nodules, consolidations. *Pearson Chi square, P < 0.05
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tuberculosis [30]. Therefore, increased susceptibility to TB
in HTLV-1-infected individuals was found to have no
association with HIV-infection. Relevant data regarding
sputum smears (taken at the time of diagnosis and after
the initiation of treatment) and M. tuberculosis cultures
were lacking in the majority of patient records.
The underlying cause surrounding the increased sus-
ceptibility to TB observed in individuals infected with
HTLV-1 remains unknown. Nonetheless, it is possible
that immunological changes induced by HTLV-1 might
also affect TB susceptibility. The protective immune re-
sponse against M. tuberculosis has been shown to be
dependent on INF-γ-activated macrophages and, inter-
estingly, HTLV-1 induces the proliferation and activation
of CD4+ T-cells, especially type 1, which consequently
produce elevated levels of INF-γ and TNF [33, 34]. It has
also been suggested that HTLV-1 infected patients may,
paradoxically, have an increased susceptibility to TB due
to impaired TNF-α production in response to M. tubercu-
losis antigens [24]. Further studies evaluating the immune
response in a larger sample of individuals coinfected with
HTLV-1/M. tuberculosis should be conducted.
The present study is limited by the fact that information
regarding the status of diabetes, alcoholism and smoking
habits, which are all recognized risk factors for TB, was
not available for all individuals. In addition, it was not pos-
sible to determine how many patients with TB and HIV
infection (in both HTLV-1 infected or uninfected groups)
were under antiretroviral treatment. As such, we cannot
exclude the possibility that HTLV-1-infected patients were
more prone to develop TB as a result of these comorbidi-
ties. It is also possible that a portion of the cohort, which
was regularly followed due to HTLV-1 infection, presented
increased rates of TB due to regular surveillance. As TB
and HTLV-1 were diagnosed in different medical settings,
51 % (17/33) of HTLV-1-infected individuals received
their TB diagnosis in a primary care setting, while 67 %
(27/40) of HTLV-1-infected individuals received a TB
diagnosis in secondary/tertiary medical units. In addition,
in over half of these coinfected patients, HTLV-1 sero-
logical status was not known at the time of TB diagnosis.
Unfortunately, it was not possible to determine the
successful rate of linkage. However, since these databases
were not very large, the results from both databases were
also visually verified. Thus, we believe that the linkage
rate was likely high. We were also unable to determine
the number of persons lost to follow-up during the study
period. It is possible that unreported cases resulted from
a myriad of factors, including loss of contact, death,
change-of-address, etc. Moreover, it is interesting to note
that the World Health Organization [35] estimates that
82 % of the true TB cases are captured by the SINAN
database in Brazil. Even under the assumption of a 100 %
accurate report rate among HTLV-1-infected individuals
and 82 % among uninfected controls, the incidence would
still be 3.3 % among HTLV versus 1.3 % (instead 1.1 %)
among HTLV negative individuals, which, nonetheless,
remains significantly different.
Conclusions
In summary, the risk of developing TB was found to be
almost three times greater in people living with HTLV-1
than among those without this viral infection. HTLV-1/TB
individuals were more commonly female, aged 50 years or
older, and had lower income and educational levels than
individuals infected only with TB. These epidemiological
features overlap those present in the profile of HTLV-1
infection. Each infection is strongly associated with greater
social vulnerability, reinforcing the neglected characteristic
of both diseases. The results presented herein indicate that,
in countries endemic for both infections, health profes-
sionals should actively monitor HTLV-1 infected patients
for respiratory symptoms.
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